Nonalcoholic fatty liver disease.

被引:27
|
作者
Younossi Z.M. [1 ]
机构
[1] The Cleveland Clinic Foundation, Department of Gastroenterology, Desk S-40, 9500 Euclid Avenue, Cleveland, 44195, OH
关键词
Fatty Liver; NASH; Nonalcoholic Fatty Liver Disease; Jejunoileal Bypass; Perhexiline;
D O I
10.1007/s11894-999-0088-1
中图分类号
学科分类号
摘要
The definition of nonalcoholic fatty liver disease has evolved in recent years. Today, it is considered a nonspecific term encompassing several clinicopathologic entities (steatosis alone, steatonecrosis, steatohepatitis and histologic alcoholic-like hepatitis) that are similar to alcoholic liver disease. Studies of nonalcoholic fatty liver disease have come to conflicting conclusions about the course of the disease. It can be argued that the disparate results are largely the result of nonuniform definitions. When histologic features such as hepatocyte ballooning, necrosis, and Mallory hyaline are seen, nonalcoholic fatty liver disease has been shown to be associated with an aggressive outcome. Steatosis alone, in contrast, appears to be benign. The current understanding of nonalcoholic fatty liver disease, the limited treatments available, and two theories of the pathogenesis of the disease are also reviewed here.
引用
收藏
页码:57 / 62
页数:5
相关论文
共 50 条
  • [1] Lipid profiles in nonalcoholic fatty liver disease.
    Adams, LA
    Keach, J
    Lindor, KD
    Angulo, P
    HEPATOLOGY, 2003, 38 (04) : 512A - 512A
  • [2] The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.
    Hamaguchi, M
    Kojima, T
    Takeda, N
    Yokomizo, C
    Taniguchi, H
    Omatsu, T
    Imose, M
    Sarui, H
    Shimazaki, M
    Kato, T
    Okuda, J
    Ida, K
    GASTROENTEROLOGY, 2005, 128 (04) : A542 - A542
  • [3] High prevalence nonalcoholic steatohepatitis in Alaska natives with nonalcoholic fatty liver disease.
    Livingston, S
    McMahon, B
    Williams, J
    Hurlburt, K
    Cagle, H
    HEPATOLOGY, 2002, 36 (04) : 726A - 726A
  • [4] Determinants of ALT levels and fibrosis in nonalcoholic fatty liver disease.
    Loria, P
    Lonardo, A
    D'Amico, R
    Leonardi, F
    Borsatti, A
    Verrone, AM
    Carulli, L
    Rudilosso, A
    Ricchi, M
    Bertolotti, M
    Ganazzi, D
    Carulli, N
    HEPATOLOGY, 2002, 36 (04) : 407A - 407A
  • [5] Prevalence of autoantibodies and autoimmune hepatitis in nonalcoholic fatty liver disease.
    Adams, LA
    Keach, J
    Lindor, KD
    Angulo, P
    HEPATOLOGY, 2003, 38 (04) : 503A - 503A
  • [6] Histopathological evaluation of nonalcoholic fatty liver disease. Automated evaluation of liver biopsies
    Abedin, Nada
    Tannapfel, Andrea
    Wild, Peter J.
    Tischoff, Iris
    PATHOLOGIE, 2022, 43 (02): : 157 - 166
  • [7] Increased hepatocyte proliferation contributes to hepatomegaly in nonalcoholic fatty liver disease.
    Mandal, AK
    Yang, SQ
    Lin, HZ
    Diehl, AM
    HEPATOLOGY, 2000, 32 (04) : 476A - 476A
  • [8] Time course of fibrosis progression in patients with nonalcoholic fatty liver disease.
    Adams, LA
    Keach, J
    Lindor, KD
    Angulo, P
    HEPATOLOGY, 2003, 38 (04) : 206A - 207A
  • [9] Nonalcoholic Fatty Liver Disease Is Related to Nonalcoholic Fatty Pancreas Disease
    van Geenen, Erwin-Jan M.
    Smits, Mark M.
    Schreuder, Tim C. M. A.
    van der Peet, Donald L.
    Bloemena, Elisabeth
    Mulder, Chris J. J.
    PANCREAS, 2010, 39 (08) : 1185 - 1190
  • [10] CROHN'S DISEASE PREDISPOSES TO LIVER FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE. A PROPENSITY MATCHED ANALYSIS
    Aggarwal, Manik
    Garg, Rajat
    Click, Benjamin H.
    Padival, Ruthvik
    Qazi, Taha
    Rieder, Florian
    Cohen, Benjamin L.
    GASTROENTEROLOGY, 2021, 160 (06) : S522 - S523